Differential effects of Parkinson's disease-associated mutations on stability and folding of DJ-1

J Biol Chem. 2004 Feb 20;279(8):6943-51. doi: 10.1074/jbc.M309204200. Epub 2003 Nov 7.

Abstract

Mutations in the PARK7/DJ-1 gene cause autosomal-recessive Parkinson's disease. In some patients the gene is deleted. The molecular basis of disease in patients with point mutations is less obvious. We have investigated the molecular properties of [L166P]DJ-1 and the novel variant [E64D]DJ-1. When transfected into non-neuronal and neuronal cell lines, steady-state expression levels of [L166P]DJ-1 were dramatically lower than wild-type [WT]DJ-1 and [E64D]DJ-1. Cycloheximide and pulse-chase experiments revealed that the decreased expression levels of [L166P]DJ-1 were because of accelerated protein turnover. Proteasomal degradation was not the major pathway of DJ-1 breakdown because treatment with the proteasome inhibitor MG-132 caused only minimal accumulation of DJ-1, even of the very unstable [L166P]DJ-1 mutant. Because of the structural resemblance of DJ-1 with bacterial cysteine proteases, we considered an autoproteolytic mechanism. However, neither pharmacological inhibition nor site-directed mutagenesis of the putative active site residue Cys-106 stabilized DJ-1. To gain further insight into the structural defects of DJ-1 mutants, human [WT]DJ-1 and both mutants were expressed in Escherichia coli. As in eukaryotic cells, expression levels of [L166P]DJ-1 were dramatically reduced compared with [WT]DJ-1 and [E64D]DJ-1. Circular dichroism spectrometry revealed that the solution structures of [WT]DJ-1 and [E64D]DJ-1 are rich in beta-strand and alpha-helix conformation. Alpha-helices were more susceptible to thermal denaturation than the beta-sheet, and [WT]DJ-1 was more flexible in this regard than [E64D]DJ-1. Thus, structural defects of [E64D]DJ-1 only become apparent upon denaturing conditions, whereas the L166P mutation causes a drastic defect that leads to excessive degradation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Circular Dichroism
  • Cycloheximide / pharmacology
  • Cysteine / chemistry
  • Cysteine Endopeptidases / metabolism
  • Cysteine Proteinase Inhibitors / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Escherichia coli / metabolism
  • Gene Deletion
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Leupeptins / pharmacology
  • Mass Spectrometry
  • Multienzyme Complexes / metabolism
  • Mutagenesis, Site-Directed
  • Mutation*
  • Neurons / metabolism
  • Oncogene Proteins / chemistry*
  • Oncogene Proteins / genetics*
  • Parkinson Disease / genetics*
  • Point Mutation
  • Proteasome Endopeptidase Complex
  • Protein Conformation
  • Protein Deglycase DJ-1
  • Protein Folding
  • Protein Structure, Secondary
  • Protein Synthesis Inhibitors / pharmacology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Temperature
  • Time Factors

Substances

  • Cysteine Proteinase Inhibitors
  • Enzyme Inhibitors
  • Intracellular Signaling Peptides and Proteins
  • Leupeptins
  • Multienzyme Complexes
  • Oncogene Proteins
  • Protein Synthesis Inhibitors
  • Cycloheximide
  • PARK7 protein, human
  • Protein Deglycase DJ-1
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex
  • Cysteine
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde